A Year After the Midterm Elections, Where Are They Now?

Political newcomers to federal and state legislatures with STEM backgrounds are bringing evidence to drafting laws, yet getting bills passed remains elusive.

Written byKatarina Zimmer
| 6 min read
us capitol stem politicians

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

ABOVE: © ISTOCK.COM, YAYAERNST

November 2018 saw a wave of candidates from all walks of science—engineering, physics, medicine, and other life sciences—win first-time positions in the House, Senate, and state legislatures across the country. Of 20 STEM candidates running for Congressional seats that The Scientist counted last year, 10 won their races, the vast majority of them Democrats as well as political newcomers. Of three who ran for Senate seats, two were successful. And of at least 23 candidates seeking positions in state legislatures, 12 won.

Many of their campaigns promised to strengthen fact-based decision making in Washington and beyond, and to counter a growing anti-science sentiment widely perceived in politics. One year on, some say they believe they’ve been able to accomplish that—not only by introducing legislation informed by their scientific background, but also by using an evidence-based approach to finding solutions on non-scientific issues, from immigration to election ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies